Scalp Psoriasis Silenced: FDA Unleashes Groundbreaking ZORYVE® Foam!

The U.S. FDA has approved Arcutis' ZORYVE® (roflumilast) topical foam 0.3% for plaque psoriasis in adults and adolescents, targeting even hard-to-treat scalp and body areas.
This once-daily, steroid-free foam offers significant relief from plaques and the "most burdensome symptom" – itch – with results seen as early as 24 hours for scalp itch.
ZORYVE foam represents a major advancement for the nearly 9 million Americans battling plaque psoriasis, providing a convenient, long-term solution for head-to-toe treatment^{6, 8}.

For millions plagued by the relentless torment of plaque psoriasis, a new era of relief has dawned. Arcutis Biotherapeutics today announced the FDA’s landmark approval of ZORYVE® (roflumilast) topical foam 0.3%, a revolutionary treatment set to transform the lives of adults and adolescents (12+) battling this chronic inflammatory skin disease⁸.

Plaque psoriasis, affecting nearly 9 million in the U.S., often unleashes its worst in hair-bearing areas like the scalp, where creams and ointments prove messy and impractical⁸. The agonizing itch, particularly on the scalp, has long been a formidable foe. But ZORYVE foam, a potent, once-daily, steroid-free phosphodiesterase-4 (PDE4) inhibitor, directly tackles this challenge^{1, 3, 5}.

Clinical trials, including the pivotal ARRECTOR study, showcased ZORYVE foam's formidable power. An astounding 66.4% of individuals saw Scalp-IGA Success (clear or almost clear skin) versus 27.8% with vehicle, and 45.5% achieved Body-IGA Success compared to 20.1%^{7, 8}. Crucially, two-thirds of users experienced clinically significant scalp itch reduction, with relief sometimes starting within 24 hours of the first application⁸.

Dr. Jennifer Soung, a clinical trial investigator, hailed it as a "much-needed solution," emphasizing its ability to "effectively clear psoriasis plaques on the body and scalp, but also provide rapid itch relief." Frank Watanabe, Arcutis’ CEO, added, "This is the fifth approval for ZORYVE in less than three years and furthers our mission to deliver new treatment options that address the urgent needs of individuals."

With its unique formulation and proven efficacy, ZORYVE foam offers patients one prescription to conquer psoriasis from head to toe, marking a significant stride forward in dermatological care. More information can be found at www.arcutis.com.

Scalp Psoriasis Silenced: FDA Unleashes Groundbreaking ZORYVE® Foam!

References

Stay Updated!